Drug advice expert

• US 20020173993A1
• Filed: 05/02/2002
• Published: 11/21/2002
• Est. Priority Date: 05/10/2001
• Status: Abandoned Application

• Current Assignee: TM Software HF.
• Original Assignee: Decode Genetics EHF Corporation
• Inventors: Helgason, Ivar Sigurjon, Sturluson, Hjortur, Schopka, Julius Helgi, Skulason, Halldor
• Application Number:
  US10/138,097
• Publication Number:
  US 20020173993A1
• Time in Patent Office: Days
• US Class Current: 705/3
• CPC Class Codes: G06Q 30/02 Marketing; Price estimation or determination; Fundraising
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 70/40 relating to drugs, e.g. their side effects or intended usage

Abstract

A user-interactive computer program provides drug advice. Drugs are grouped according to their clinical and chemical characteristics in a supporting data base. For each drug, a drug database contains detailed information on pharmacokinetics, pharmaco-dynamics and drug-specific details. In response to user interaction with areas displayed on the screen, the computer program obtains pertinent drug interaction information from the database. With the obtained information, the computer program supports display of graphical screen views. Contents of the screen views include symbols for indicating respective drugs, geometrically distinguishing lines for indicating interaction between drugs, and text descriptions of drug information. Further included in the screen views are respective symbols for indicating drug warnings for pregnant or lactating women and sportspersons. Color coding may also be employed in the screen views to indicate degree of effect or warning.

Claims

1. A method for providing expert drug advice, comprising:

representing drugs as nodes in a graph in a computer display window; and

graphically representing a property associated with a first represented drug.

2. The method of claim 1, wherein the graphically represented property is interaction between the first drug and a second represented drug.

3. The method of claim 2, wherein the interaction is indicated by a line connecting nodes representing the first and second drugs.

4. The method of claim 3, wherein the line further indicates whether at least one of the first drug and second drug increases/decreases effectiveness of the other drug.

6. The method of claim 4, further comprising:

using plus signs (“

+”

) to indicate increased effectiveness; and

using minus signs (“

−

”

) to indicate decreased effectiveness.

7. The method of claim 3, wherein the line further indicates a strength of the interaction.

8. The method of claim 7, further comprising:

adjusting thickness of the line based on the strength of the interaction.

9. The method of claim 7, further comprising:

color-coding the line based on the strength of the interaction.

11. The method of claim 3, wherein any combination of extended effects, additive effects and chain reactions is illustrated.

12. The method of claim 2, wherein the represented drugs are from a drug list.

13. The method of claim 12, further comprising:

indicating interactions between drugs on the drug list.

14. The method of claim 12, further comprising:

representing a proposed drug as a node; and

indicating interactions between the proposed drug and drugs on the drug list.

15. The method of claim 12, further comprising:

representing a proposed drug as a node; and

indicating interactions between the proposed drug and other displayed drugs.

16. The method of claim 2, wherein drug interaction representation is responsive to patient data.

17. The method of claim 16, further comprising:

maintaining, in a database, at least one of historical and current patient data.

18. The method of claim 16, wherein patient data comprises drug dosages.

19. The method of claim 1, wherein the property is a warning associated with the drug.

20. The method of claim 19, wherein the graphically represented warning of the first drug is related to at least one of:

allergic reactions, pregnancy, lactation, QT-interval prolongation, impaired ability to operate a motor vehicle/machinery, drug dependence, competitive sports, photosensitivity, general warnings, side effects, overdose, affect on at least one organ, and food/drug interactions.

21. The method of claim 20, wherein the graphically represented warning related to impaired ability to operate a motor vehicle/machinery includes warnings based on effects due to any of blurred vision, muscle relaxation, drowsiness and dizziness.

22. The method of claim 19, further comprising:

indicating possible allergic reactions of the first drug by blinking the associated node.

23. The method of claim 19, further comprising:

indicating severity of the warning using color coding.

24. The method of claim 19, further comprising:

providing soft switches with which a user can selectively enable/disable different warning types.

25. The method of claim 1, further comprising:

providing a small window mode in which limited information is provided in a small display window.

26. The method of claim 1, further comprising:

providing a large window mode in which detailed information is provided in a large display window.

27. The method of claim 26, further comprising:

providing a small window mode in which limited information is provided in a small display window.

28. The method of claim 27, further comprising:

passing from the small window mode to the large window mode in response to user action in the small display window.

29. The method of claim 1, further comprising:

integrating software that performs the steps of claim 1 with an independently-developed application; and

integrating the window with graphical output of the application.

30. The method of claim 29, wherein the independently-developed application is a drug prescription software application.

31. The method of claim 29, further comprising:

providing an application program interface (API) for interfacing with the independently-developed application.

32. The method of claim 31, the independently-developed application further providing information about a patient through the API.

33. The method of claim 1, further comprising:

including a graphical help function.

34. The method of claim 1, further comprising:

maintaining at least one database for storing drug property information; and

retrieving said information from said at least one database.

35. The method of claim 34, wherein said stored information comprises at least one of pharmacokinetic, pharmacodynamic and drug-specific information.

36. The method of claim 34, further comprising:

indexing the database according to medical standard classifications.

37. The method of claim 1, further comprising:

displaying additional information when a cursor is made to hover over an interactive spot.

38. The method of claim 37, wherein the additional information includes a link to other information.

39. The method of claim 37 wherein the interactive spot is a drug node and the additional information includes details and references regarding the drug.

40. The method of claim 1, further comprising:

color-coding a drug node with a first color to indicate drug allergies, and with a second color to indicate possible cross-allergies.

41. The method of claim 1, further comprising:

color coding a node to indicate degree of certainty of an allergic reaction.

42. The method of claim 1, wherein the drug property is represented based on patient characteristics.

43. The method of claim 42, wherein patient characteristics include any of age, gender, current drug list, diagnosis, symptoms, cost and allergies.

44. Computer apparatus comprising:

a database containing drug information;

a digital processor coupled to the database; and

a driver executing on the digital processor which

accesses the database,

represents drugs as nodes in a graph in a display window, and

graphically represents a property associated with a first represented drug based on the drug information.

45. The computer apparatus of claim 44, wherein the graphically represented property is interaction between the first drug and a second represented drug.

46. The computer apparatus of claim 45, wherein the interaction is indicated by a line connecting nodes representing the first and second drugs.

47. The computer apparatus of claim 46, wherein the line further indicates whether at least one of the first drug and second drug increases/decreases effectiveness of the other drug.

49. The computer apparatus of claim 47, wherein plus signs (“

+”

) indicate increased effectiveness, and minus signs (“

−

”

) indicate decreased effectiveness.

50. The computer apparatus of claim 46, wherein the line further indicates strength of the interaction.

51. The computer apparatus of claim 50, wherein thickness of the line indicates strength of the interaction.

52. The computer apparatus of claim 50, wherein the line is color-coded based on the strength of the interaction.

54. The computer apparatus of claim 46, wherein any combination of extended effects, additive effects and chain reactions is illustrated.

55. The computer apparatus of claim 45, wherein the represented drugs are from a drug list.

56. The computer apparatus of claim 55, wherein interactions between drugs on the drug list are indicated.

57. The computer apparatus of claim 55, wherein a proposed drug is represented as a node, and interactions between the proposed drug and drugs on the drug list are indicated.

58. The computer apparatus of claim 55, wherein a proposed drug is represented as a node, and interactions between the proposed drug and other displayed drugs are indicated.

59. The computer apparatus of claim 45, wherein drug interaction representation is responsive to patient data.

60. The computer apparatus of claim 59, further comprising:

a database for storing at least one of historical and current patient data.

61. The computer apparatus of claim 59, wherein patient data comprises drug dosages.

62. The computer apparatus of claim 45, wherein the property is a warning associated with the drug.

63. The computer apparatus of claim 62, wherein the graphically represented warning of the first drug is related to at least one of:

allergic reactions, pregnancy, lactation, QT-interval prolongation, impaired ability to operate a motor vehicle/machinery, drug dependence, competitive sports, photosensitivity, general warnings, side effects, overdose, affect on at least one organ, and food/drug interactions.

64. The computer apparatus of claim 63, wherein the graphcially represented warning related to impaired ability to operate a motor vehicle/machinery includes warnings based on effects due to any of blurred vision, muscle relaxation, drowsiness and dizziness.

65. The computer apparatus of claim 62, wherein possible allergic reactions of the first drug are indicated by blinking the associated node.

66. The computer apparatus of claim 62, wherein the warning is color-coded to indicate severity.

67. The computer apparatus of claim 62, wherein the driver further displays soft switches with which a user can selectively enable/disable different warning types.

68. The computer apparatus of claim 44, wherein the driver displays limited information in a small display window.

69. The computer apparatus of claim 44, wherein the driver displays detailed information in a large display window.

70. The computer apparatus of claim 69, wherein the driver displays, at any time, one of the large display window, and a small display window in which limited information is provided.

71. The computer apparatus of claim 70, wherein the large display window is displayed in response to a user action in the small display window.

72. The computer apparatus of claim 44, wherein the driver is integrated with an independently-developed application, and the driver'"'"'s display is integrated with graphical output of the application.

73. The computer apparatus of claim 72, wherein the independently-developed application is a drug prescription software application.

74. The computer apparatus of claim 72, further comprising:

an application program interface (API) for interfacing with the independently-developed application.

75. The computer apparatus of claim 74, wherein the independently-developed application further provides information about a patient through the API.

76. The computer apparatus of claim 44, further comprising:

a graphical help function.

77. The computer apparatus of claim 44, wherein drug information in the database comprises at least one of pharmacokinetic, pharmacodynamic and drug-specific information.

78. The computer apparatus of claim 44, wherein the database is indexed according to medical standard classifications.

79. The computer apparatus of claim 44, wherein the driver displays additional information when a cursor is made to hover over an interactive spot.

80. The computer apparatus of claim 79, wherein the additional information includes a link to other information.

81. The computer apparatus of claim 79 wherein the interactive spot is a drug node and the additional information includes details and references regarding the drug.

82. The computer apparatus of claim 44, wherein the driver colors a drug node with a first color to indicate drug allergies, and with a second color to indicate possible cross-allergies.

83. The computer apparatus of claim 44, wherein the driver colors a node to indicate degree of certainty of an allergic reaction.

84. The computer apparatus of claim 44, wherein the drug property is represented based on patient characteristics.

85. The computer apparatus of claim 84, wherein patient characteristics include any of age, gender, current drug list, diagnosis, symptoms, cost and allergies.

86. Computer apparatus comprising:

means for representing drugs as nodes in a graph in a display window; and

means for graphically representing a property associated with a first represented drug.

87. A drug advice expert computer program product, the computer program product comprising a computer usable medium having computer readable code thereon, including program code which:

represents drugs as nodes in a graph in a display window; and

graphically represents a property associated with a first represented drug.